Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits

E. H. Herman, V. J. Ferrans, W. Jordan, B. Ardalan

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


To determine whether ICRF-187 (NSC-169780) would alter chronic daunorubicin (NSC-82151) cardiac toxicity, male New Zealand rabbits were given 3.2 mg/kg of daunorubicin iv alone or 30 minutes after 12.5 or 25.0 mg/kg of ICRF-187 ip at 3-week intervals. Control rabbits received either saline iv or ICRF-187 (12.5 or 25.0 mg/kg) ip on the same schedule. Three weeks after the fifth injection, the animals were sacrificed. The frequency and extent of cellular alterations were graded on a scale of 0 to 4. Lesions consisting mainly of vacuolization and myofibrillar loss were noted in the hearts of all 12 rabbits given daunorubicin alone. The severity ranged from 1 to 3 (average 1.8). In contrast, no abnormalities were noted in one of five (12.5 mg/kg) and three of seven (25.0 mg/kg) ICRF-treated rabbits. The remaining eight hearts from both pretreatment groups displayed minimal alterations ranging from 0.5 to 1.0 (average 0.9). Thus, concurrent administration of the antineoplastic agent ICRF-187 may offer a means of reducing chronic daunorubicin cardiac toxicity.

Original languageEnglish (US)
Pages (from-to)85-97
Number of pages13
JournalResearch Communications in Chemical Pathology and Pharmacology
Issue number1
StatePublished - Jan 1 1981
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Toxicology
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits'. Together they form a unique fingerprint.

Cite this